Are there clinically significant interactions between TOPAMAX and other medications frequently used to treat migraine?
The potential for pharmacokinetic interactions between TOPAMAX and other medications is somewhat limited because TOPAMAX is not highly protein bound nor is it extensively metabolized in the liver. TOPAMAX administration was not associated with clinically significant effects on sumatriptan, propranolol, or dihydroergotamine. TOPAMAX has been associated with an increase in amitriptyline and decreased valproic acid plasma concentrations.